Tencent-backed US drug discovery firm Atomwise closes $123m Series B round

Atomwise, which uses artificial intelligence for structure-based small molecule drug discovery, has raised $123 million in an oversubscribed Series B round, according to a company statement on Tuesday. The San Francisco-based firm said it will use the proceeds to scale and build its own pipeline of experimental drugs.